65,437 trials
Hyperphosphatemia
Primary: Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms — 1.4; 0.6 mg/dL — p=0.01
Parkinson's Disease · Off Episodes of Parkinson Disease
Primary: Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method…
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…
End Stage Renal Disease · Chronic Kidney Disease Stage 5 · ESRD
Primary: Change in Mean Weekly Interdialytic Weight Gain (IDWG) — -0.26; -0.23 kilograms — p=0.46
Non-radiographic Spondyloarthritis
Primary: The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16 — 68; 70; 50…
Amyotrophic Lateral Sclerosis
Primary: Change in Percent of Expected Lung Force Vital Capacity — -1.25 % Expected Forced Vital Capacity
Metastatic Renal Cell Cancer
Primary: Median Progression-free Survival — 8.8 months
Left Ventricular Dysfunction
Primary: An MR Spectroscopy Showing Signal to Noise Ratio to Determine the Level of Heart Failure — 7 Ratio — p=<0.05
Healthy
Primary: Total Volume of Distribution (VT) of [18F]PGM299 in the Cerebellar Grey Matter (GM) for Each PET Scan — 1.211; 1.247; 1.349; 1.683 milliliter per cubic centimeter(mL/cm^3)
Lumbar Spinal Stenosis
Primary: Percentage of Subjects With Clinically Significant Improvement in Outcomes — 56.3; 56.0 percentage of subjects
Cystic Fibrosis
Primary: Safety as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 56; 15 participants
Healthy
Primary: Total Number of Stool Images Collected — 2731 images
Patients With Post Orthotopic Heart Transplantation Status
Primary: To Measure Free Fatty Acid by Imaging Patients With Increased Levels of iNOS Using [18F](+/-)NOS.
Immunosuppression · Stem Cell Transplant · Bone Marrow Transplant
Primary: Median Tacrolimus Sublingual Trough Level — 11.3 ng/mL
Carcinoma, Hepatocellular
Primary: Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS) — 19.0; 21.5; 24.2; 17.9 Months